

# Ott Laius

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9013691/publications.pdf>

Version: 2024-02-01

10  
papers

637  
citations

1478505

6  
h-index

1372567

10  
g-index

10  
all docs

10  
docs citations

10  
times ranked

703  
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. <i>BMC Health Services Research</i> , 2010, 10, 153.	2.2	201
2	Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010, 10, 707-722.	1.4	131
3	Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. <i>Frontiers in Pharmacology</i> , 2014, 5, 106.	3.5	107
4	Policies to Enhance Prescribing Efficiency in Europe: Findings and Future Implications. <i>Frontiers in Pharmacology</i> , 2010, 1, 141.	3.5	90
5	Use of Generics—A Critical Cost Containment Measure for All Healthcare Professionals in Europe?. <i>Pharmaceuticals</i> , 2010, 3, 2470-2494.	3.8	76
6	Use of a national database as a tool to identify primary medication non-adherence: The Estonian ePrescription system. <i>Research in Social and Administrative Pharmacy</i> , 2018, 14, 776-783.	3.0	11
7	Adherence to osteoporosis medicines in Estonia—a comprehensive 15-year retrospective prescriptions database study. <i>Archives of Osteoporosis</i> , 2017, 12, 59.	2.4	7
8	Trends in and relation between hip fracture incidence and osteoporosis medication utilization and prices in Estonia in 2004–2015. <i>Archives of Osteoporosis</i> , 2017, 12, 48.	2.4	6
9	Use of drugs against osteoporosis in the Baltic countries during 2010–2014. <i>Medicina (Lithuania)</i> , 2016, 52, 315-320.	2.0	4
10	Featured Article: Transcriptional landscape analysis identifies differently expressed genes involved in follicle-stimulating hormone induced postmenopausal osteoporosis. <i>Experimental Biology and Medicine</i> , 2017, 242, 203-213.	2.4	4